Israel-based AION Labs, an AI-enabled drug discovery partnership between global pharma and tech companies, has launched ProPhet, a startup using artificial intelligence to locate small molecules for drug discovery.
ProPhet was established following AION Labs' startup challenge focused on AI-powered drug discovery of new high-affinity small molecules.
The aim is to address the market need to speed...
Google DeepMind announced the launch of AlphaProteo, an AI system to help biological and health researchers design novel, high-strength proteins that bind to target molecules with accuracy and strength.
AlphaProteo was trained on the Protein Data Bank (PDB) that enables breakthroughs in science and education by providing access and tools for exploration, visualization and analysis of...
Israeli startup CytoReason, maker of a computation model to map and compare treatments, announced it secured $80 million in funding.
Pfizer, OurCrowd, NVIDIA and Thermo Fisher Scientific participated in the round.
WHAT IT DOES
CytoReason offers life sciences companies AI-enabled tools to gather data-driven and molecular-level insights to improve phase 2 success in clinical trials and optimize...
Amazon Web Services (AWS) announced that it is collaborating with EvolutionaryScale, an AI company focused on biology, to give scientists and researchers access to the startup's ESM3 language models via AWS to advance drug discovery by allowing for the creation of new proteins.
Yesterday, EvolutionaryScale, founded by former researchers at Meta’s AI research lab, announced it secured $142 million...
Google Research and Google DeepMind recently released a paper announcing the creation of a new LLM for drug discovery and therapeutic development dubbed Tx-LLM, fine-tuned from PaLM-2.
Tx-LLM utilizes the tech giant's PaLM-2, its generative AI technology that uses Google's LLMs to answer medical questions.
The drug discovery-focused LLM was trained using 709 datasets to target 66 tasks across...
Israel-based AION Labs, an AI-enabled drug discovery partnership between global pharma and tech companies, announced the launch of a new startup company CombineAble.AI, which will speed up the development of therapeutics by addressing challenges associated with antibody design.
CombinAble.AI was formed following an AION Labs startup challenge aimed at developing an AI-based solution for...
Publicly listed Daewoong Pharmaceutical has recently unveiled its AI-driven drug development system, powered by a database of hundreds of millions of pre-processed compounds.
WHAT IT'S ABOUT
Over the past two years, researchers of the Seoul-based pharma giant have sought to solve perennial issues in the development of novel drugs, particularly high cost and low efficiency.
Serving as the...
Absci, a startup focused on developing generative AI antibody discovery technology, announced a potential $247 million partnership with pharma giant AstraZeneca to focus on expediting the discovery of novel cancer treatments with the help of genAI technology.
The project will leverage Absci's Integrated Drug Creation platform – which combines scalable wet lab technologies with AI, and facilitates...
German pharmaceutical company Boehringer Ingelheim and tech giant IBM are teaming up to harness the power of genAI and foundation models to further biologic drug discovery.
The partnership leverages IBM’s foundation model technologies, consisting of pre-trained, large-scale neural network architectures, to accelerate the identification of novel antibodies vital for therapeutic development.
These...
Philadelphia-based AI-enabled biotech company Vivodyne announced it closed a $38 million seed funding round led by Khosla Ventures.
CS Ventures, Kairos Ventures, Bison Ventures and MBX Capital also participated in the round.
WHAT IT DOES
Vivodyne is a drug discovery company that uses clinically predictive AI to help identify therapeutic targets and predict a patient's response to a drug by...
